|
Post by zuegirdor on Sept 4, 2018 10:29:38 GMT -5
Sanofi was bigger due to fda approval. The part I like best is the opportunity to replay p3 trial outcomes, any achom news, and fda approval of Inhaled TrepT. Been here done this,,, right ? 😎 Perhaps what you say is true, rockstarrick , but this new Agreement validates Technosphere technology and gives UTC the right to develop additional API at $10 million upfront plus double-digit royalties for each API. Long-term investors, like you, know that TS-API possibilities are endless.
What if UTC decides to develop a TS-API for migraines? The market would eclipse insulin.
This Agreement is exciting news and, as another PB member pointed out to me earlier this morning, it's very good news that the collaboration to develop additional TS-APIs is with a big pharmaceutical company rather than a venture capitalist.
I know so many that "TS-API for migraines" could help! Might even work for my opthalmic migraines - you know, the ones where you see the aura or psychedelic halo in the middle of your field of vision?
|
|
|
Post by lakers on Sept 4, 2018 10:29:44 GMT -5
11/19/16 by Lakon: Serious traction for Afrezza is a goal, the #1 goal. There are backup plans to provide the time needed to reach the goal. You may not like all of the alternatives, but the goal is worldwide domination by Afrezza for dramatically improved outcomes for PWD to prevent a catastrophe. As Al Mann stated, if something is not done about the trajectory of diabetes growth globally, it will bankrupt the entire system. Don't expect Afrezza to fix everything at once, just because it's there. The same goes for Epi, RLS, etc. Put them all together, and there may be enough time to get serious traction. You also have to realize that the standard of care is WRONG. Convincing people to change is hard. Back on topic, inhaled treprostinil (Tyvaso) can be improved by a new formulation on Technosphere. The market is ripe for competition, and the incumbent is an innovator who may wish to partner to maintain position. There is precedence and promise here. Read more: mnkd.proboards.com/thread/6389/inhaled-trespostinil-pah-tyvaso-450m?page=2#ixzz5Q9CFPFMe
|
|
|
Post by mango on Sept 4, 2018 10:37:36 GMT -5
Amazing. Perfect partner I would say. ”On the very same day 21 years ago, we enabled the development of treprostinil into a practical treatment thanks to an invention of the late Al Mann – the discrete, ambulatory, programmable, parenteral infusion pump called the MiniMed 407c,” said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. “By marrying our molecule and MiniMed’s device, Remodulin® was born. As we now move into the second generation of United Therapeutics products, we are proud to once again team with Al Mann’s brilliance, this time with his Dreamboat®, Bluhale® and Cricket® devices for inhalation. I believe these revolutionary new inhalation devices will accomplish for Tyvaso® what our recently-approved Implantable System for Remodulin, pending RemUnity™ system and recently-acquired Trevyent® product represent for Remodulin – a further step toward a next generation of treprostinil drug-device systems that enhance options for patients, their families and their prescribers.” I have followed Martine Rothblatt and United Therapeutics for a long time. Rothblatt is a genius on a par with Al Mann, and like him, started in an unrelated field (satellite radio) before being drawn to health care. She is playing with her own money, and her CV is worth a read. en.wikipedia.org/wiki/Martine_RothblattWow, very cool! Female version of Al
|
|
|
Post by jonny80s on Sept 4, 2018 10:45:19 GMT -5
No what would be really great.... If United Therapeutics takes a stake in mnkd.
|
|
|
Post by celo on Sept 4, 2018 10:59:43 GMT -5
|
|
|
Post by peppy on Sept 4, 2018 11:01:52 GMT -5
|
|
|
Post by mango on Sept 4, 2018 11:05:28 GMT -5
Amazing. Perfect partner I would say. ”On the very same day 21 years ago, we enabled the development of treprostinil into a practical treatment thanks to an invention of the late Al Mann – the discrete, ambulatory, programmable, parenteral infusion pump called the MiniMed 407c,” said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. “By marrying our molecule and MiniMed’s device, Remodulin® was born. As we now move into the second generation of United Therapeutics products, we are proud to once again team with Al Mann’s brilliance, this time with his Dreamboat®, Bluhale® and Cricket® devices for inhalation. I believe these revolutionary new inhalation devices will accomplish for Tyvaso® what our recently-approved Implantable System for Remodulin, pending RemUnity™ system and recently-acquired Trevyent® product represent for Remodulin – a further step toward a next generation of treprostinil drug-device systems that enhance options for patients, their families and their prescribers.” I have followed Martine Rothblatt and United Therapeutics for a long time. Rothblatt is a genius on a par with Al Mann, and like him, started in an unrelated field (satellite radio) before being drawn to health care. She is playing with her own money, and her CV is worth a read. en.wikipedia.org/wiki/Martine_RothblattHer daughter was diagnosed with PAH. www.google.com/amp/s/www.forbes.com/sites/kathryndill/2016/12/01/things-that-are-of-value-require-cost-martine-rothblatt-on-solving-the-unsolvable/amp/
|
|
|
Post by mnholdem on Sept 4, 2018 11:17:57 GMT -5
Absolutely! What a remarkable person!
Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. Rothblatt graduated from University of California, Los Angeles with a combined law and MBA degree in 1981, then began to work in Washington, D.C., first in the field of communications satellite law, and eventually in life sciences projects like the Human Genome Project.[5] She is the founder and Chairwoman of the Board of United Therapeutics. She was also the CEO of GeoStar and the creator of SiriusXM Satellite Radio.[6] She was the top earning CEO in biopharmaceutical industry in 2018.
Rothblatt is a well-known voice for medical and pharmaceutical innovation. In 1994, motivated by her daughter being diagnosed with life-threatening pulmonary hypertension,[22] Rothblatt entered the world of the life sciences by first creating the PPH Cure Foundation and later by founding a medical biotechnology company (United Therapeutics, 1996).[16] At that time she also began studying for a Ph.D. in medical ethics at the Barts and The London School of Medicine and Dentistry, Queen Mary University of London. The degree was granted in June 2001 based upon her dissertation on the conflict between private and public interests in xenotransplantation. This thesis, defended before England's leading bioethicist John Harris, was later published by Ashgate House under the title Your Life or Mine.[23] In 2013, Rothblatt was the highest-paid female CEO in America, earning $38 million.[24] Rothblatt received a total compensation of $31,581,896 in 2014. On December 5, 2017 North Carolina State University conferred her an honorary Doctor of Sciences degree.[25] On May 11, 2010 she was awarded an honorary doctorate by Ben Gurion University of the Negev in recognition of her accomplishments in satellite communications and biotechnology.[26] In April 2008, Rothblatt was elected a Member of the American Philosophical Society.[27]
As of April 2018, Rothblatt earned a compensation package worth $37.1 million from United Therapeutics. The majority of the compensation package is for stock options.[7]
Source: en.wikipedia.org/wiki/Martine_Rothblatt
|
|
|
Post by lakers on Sept 4, 2018 11:21:58 GMT -5
No what would be really great.... If United Therapeutics takes a stake in mnkd. That could happen when Mnkd is valuated at $2.55B, $16.7/sh, when TreT finishes Phase 3. BoD doesn’t want to give away the co at cheap valuations. When Afrezza was approved, Mnkd reached $55/sh.
|
|
|
Post by ilovekauai on Sept 4, 2018 11:37:32 GMT -5
Well how do you like these Pineapples! What a delicious morning to awaken to! Great news for a great company. I'm tempted to gloat but won't. We true longs always knew this day was coming, we never lost the torch, and here it is. A big CONGRATS to Michael C and the entire team at MNKD. You guys totally rock it!
|
|
|
Post by mnholdem on Sept 4, 2018 11:42:28 GMT -5
United Therapeutics is a biotechnology company. It is listed on the NASDAQ [UTHR]. Its headquarters are located in Silver Spring, Maryland, with additional facilities in Research Triangle Park, North Carolina; Magog, Quebec; Melbourne, Florida; and Manchester, New Hampshire.
History
United Therapeutics was founded in 1996 by Martine Rothblatt, an American lawyer, author, and entrepreneur, who previously created Sirius XM. In 1994, Rothblatt's young daughter was diagnosed with a fatal orphan disease, pulmonary arterial hypertension (PAH). Rothblatt sold her telecom stock and started the $3 million PPH Cure Foundation to fund PAH research. By 2002 the FDA had approved United Therapeutics new drug Remodulin an alternative to GlaxoSmithKline's Flolan. In 2002 Remodulin was priced at $90,000 per year and within "a year annual sales were $50 million." By 2010 sales rose to $300 million.
By 2010, "United Therapeutics shares had increased 800% from 1999 when the company went public.
By October 2012, United Therapeutics had a market capitalization of US$3 billion. Rothblatt received a total compensation of $31,581,896 in 2014. According to the "annual collaborative report" from Equilar and The New York Times, Rothblatt ranked 24th in the list of "200 highest-paid CEOs of large publicly traded companies" and fourth in the list of biopharmaceutical executives with the highest total compensation.
On December 31, 2014, United Therapeutics announced a deal with DEKA for the development of a potential technology breakthrough in the subcutaneous delivery of its Remodulin (treprostinil) injection to patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system. According to Martine Rothblatt, “The new DEKA semi-disposable pump system will advance the convenience and delivery of subcutaneous Remodulin”. Rothblatt is a collaborator on inventions with DEKA's founder Dean Kamen.
Medicines
As of 2017, United Therapeutics markets five medicines with over a dozen new medicines in development. The marketed medicines are Remodulin, Tyvaso, Orenitram and Adcirca for pulmonary arterial hypertension, and Unituxin for neuroblastoma. Clinical trials of new medicines related to pulmonary hypertension include INCREASE for interstitial lung disease, SOUTHPAW for heart failure, PERFECT for COPD and SAPPHIRE for gene therapy. Other medicines being developed include dinutuximab for Small Cell Lung Cancer, and meter dose inhaler preparations for pulmonary selective vasodilation.
United Therapeutics generally develops medicines under a pharmacogenomic paradigm that emphasizes association of clinical trial outcomes with genetic polymorphisms identified from whole genome sequencing of patients enrolled in clinical studies. The company has a goal of ultimately providing prescribing information that includes differential expectations based upon bioinformatic knowledge gained from genome sequencing.
United Therapeutics is also developing a unique type of biologic medicinal product known as a manufactured organ. This type of biologic would be transplanted into the patient as a substitute for a failing organ. The company has regenerative medicine products such as these being developed via xenotransplantation, allogenic recellularization and autologous bioprinting technologies.
Source: en.wikipedia.org/wiki/United_Therapeutics
---
This bio might give MNKD shareholders an idea of some additional API they may be looking to develop with MannKind.
|
|
|
Post by rockstarrick on Sept 4, 2018 11:44:40 GMT -5
I am pleasantly surprised (my Calls that I bought in anticipation of the ADA are looking a lot healthier). It makes sense for UTC since this is an area they have sewn up and they don't want the competition. There are some other interesting thoughts - sales from this do not count towards the Deerfield milestone payment. It also alters the dynamic with Deerfield. I think it’s more they want to couple their drug with our, (Al Mann’s) delivery device, as they did with minimed. It’s in the press release. Congrats on your calls.
|
|
|
Post by lakers on Sept 4, 2018 11:49:13 GMT -5
Particularly nice to see Al Mann being honored. Does this mean all of the shorts will finally be gone? If UT has a sales force maybe they can help mnkd spread the word about Afrezza also. Co-promo ops. UTHR’s sale force is expert at allaying the lung issue fear which is the key impediment to PCP, endo adoption. More importantly, UTHR partnership helps validate the TS approach. IMHO, we are in the very early innings of a championship run. Warrants conversion might be possible. Higher valuation begets easy access to capital market.
|
|
|
Post by goyocafe on Sept 4, 2018 11:58:17 GMT -5
Anyone else see this in the release? “United Therapeutics will manufacture the long-term commercial supplies.” Does this mean that the IP for manufacturing TS is going to be shared with UTHR? I hope they button that up to be sure it doesn’t get away from them.
|
|
|
Post by peppy on Sept 4, 2018 12:01:58 GMT -5
Anyone else see this in the release? “United Therapeutics will manufacture the long-term commercial supplies.” Does this mean that the IP for manufacturing TS is going to be shared with UTHR? I hope they button that up to be sure it doesn’t get away from them. I believe it means MNKD will get their supply of treprostinil from UTHR. correct me if I am wrong please.
|
|